Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...

Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of ...

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common ...

Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities With new manufacturing capacity, Novartis will be able to produce 100% of its key ...

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer ...

Having elevated levels of lipoprotein (a), or Lp (a) for short, increases a person’s chances of having a cardiovascular event such as a stroke or a heart attack. It was after having two heart attacks ...

Novartis Entresto® US patent upheld by US Court of Appeals ...

Priority Review based on ASC4FIRST Phase III study with Scemblix® data first to show significantly improved molecular response and a favorable safety and tolerability profile compared to standard of ...

Transaction reinforces company’s strategic focus on developing next-generation treatment options for patients living with cancer Mariana Oncology is a preclinical-stage biotechnology company focused ...

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant ...

The SMART study supplements a growing body of evidence on the use of Zolgensma in a patient population older and heavier (1.5 – 9.1 years of age) than the children treated in previous clinical studies ...